Biocardia Inc (BCDA)

$1.36 +0.01 (0.74%)
Market Cap 7.90M
Revenue (ttm) 60,000.00
Net Income (ttm) -7.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -13,250.00%
Debt to Equity Ratio 0.00
Volume 367,000
Avg Vol 897,538
Day's Range N/A - N/A
Shares Out 5.81M
Stochastic %K 58%
Beta 0.80
Analysts Sell
Price Target $15.50

Company Profile

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 226 0120
Fax: 650 631 3731
Address:
320 Soquel Way, Sunnyvale, United States
RIPJAWx
RIPJAWx Oct. 3 at 4:01 PM
$BCDA get ready pump coming before close and after hours 🚀🚀🚀
1 · Reply
LORAXX
LORAXX Oct. 3 at 2:17 PM
$BCDA This one is flying under the radar.
0 · Reply
Tom678
Tom678 Oct. 3 at 10:23 AM
$BCDA
0 · Reply
Raycloser
Raycloser Oct. 2 at 1:49 PM
$BCDA what’s BCDA really worth in terms of market cap
0 · Reply
NoQinyoface
NoQinyoface Oct. 2 at 1:34 PM
$BCDA This could soar within the month.
0 · Reply
DARKP00L
DARKP00L Oct. 2 at 12:04 PM
$BCDA 08:04 on Oct. 02 2025 BioCardia Regains Compliance With Nasdaq Listing Requirements #tradeideas
0 · Reply
Tom678
Tom678 Oct. 2 at 12:02 PM
$BCDA $DJT $PAVS $SCPH $TAOP BCDA amazing news !!!! 😁😁
0 · Reply
stocktuit
stocktuit Oct. 2 at 12:01 PM
$BCDA Announced Compliance with Nasdaq Listing Requirements
0 · Reply
IJ90
IJ90 Oct. 2 at 10:26 AM
$BCDA Today is the 3rd day after the Nasdaq compliance deadline — usually the most common day for official confirmation filings (8-K). BCDA stated earlier that all requirements are met, so we’re likely waiting for Nasdaq’s formal letter any moment now. Stay tuned — big update could drop today. 🚀👀
0 · Reply
Tom678
Tom678 Oct. 1 at 6:57 PM
$BCDA
0 · Reply
Latest News on BCDA
BioCardia Regains Compliance with Nasdaq Listing Requirements

Oct 2, 2025, 8:00 AM EDT - 2 days ago

BioCardia Regains Compliance with Nasdaq Listing Requirements

BioCardia Announces Pricing of Up To $12 Million Public Offering

Sep 18, 2025, 9:15 AM EDT - 16 days ago

BioCardia Announces Pricing of Up To $12 Million Public Offering

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up

Sep 18, 2025, 7:00 AM EDT - 16 days ago

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up

BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025

Sep 4, 2025, 9:00 AM EDT - 4 weeks ago

BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025

BioCardia, Inc. (BCDA) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 8:37 PM EDT - 7 weeks ago

BioCardia, Inc. (BCDA) Q2 2025 Earnings Call Transcript

BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results

Aug 11, 2025, 9:15 AM EDT - 7 weeks ago

BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results

BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025

Aug 6, 2025, 3:18 PM EDT - 2 months ago

BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025

BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter

Aug 4, 2025, 6:00 AM EDT - 2 months ago

BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

May 21, 2025, 8:30 AM EDT - 4 months ago

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

BioCardia, Inc. (BCDA) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:40 PM EDT - 5 months ago

BioCardia, Inc. (BCDA) Q1 2025 Earnings Call Transcript

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

May 14, 2025, 4:05 PM EDT - 5 months ago

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

May 9, 2025, 4:28 PM EDT - 5 months ago

BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

Apr 11, 2025, 9:15 AM EDT - 6 months ago

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 11:30 PM EDT - 6 months ago

BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript

BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

Mar 31, 2025, 1:39 PM EDT - 6 months ago

BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

BioCardia Reports 2024 Business Highlights and Financial Results

Mar 26, 2025, 4:30 PM EDT - 6 months ago

BioCardia Reports 2024 Business Highlights and Financial Results

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

Mar 21, 2025, 8:30 AM EDT - 7 months ago

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

Mar 10, 2025, 9:15 AM EDT - 7 months ago

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

Feb 27, 2025, 9:15 AM EST - 7 months ago

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

Feb 13, 2025, 8:30 AM EST - 8 months ago

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

Jan 27, 2025, 9:15 AM EST - 8 months ago

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

Dec 4, 2024, 8:30 AM EST - 10 months ago

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:49 PM EST - 11 months ago

BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

Sep 18, 2024, 8:30 AM EDT - 1 year ago

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Sep 9, 2024, 4:05 PM EDT - 1 year ago

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

Aug 29, 2024, 8:30 AM EDT - 1 year ago

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

Aug 21, 2024, 7:00 AM EDT - 1 year ago

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

BioCardia, Inc. (BCDA) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 7:53 PM EDT - 1 year ago

BioCardia, Inc. (BCDA) Q2 2024 Earnings Call Transcript

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

Aug 13, 2024, 4:30 PM EDT - 1 year ago

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

Jul 17, 2024, 7:00 AM EDT - 1 year ago

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

Jun 7, 2024, 7:00 AM EDT - 1 year ago

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

BioCardia Announces Reverse Stock Split

May 21, 2024, 5:00 PM EDT - 1 year ago

BioCardia Announces Reverse Stock Split

BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript

May 14, 2024, 11:00 PM EDT - 1 year ago

BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

May 14, 2024, 4:02 PM EDT - 1 year ago

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024

May 9, 2024, 7:00 AM EDT - 1 year ago

BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024

BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

May 1, 2024, 7:00 AM EDT - 1 year ago

BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

Apr 25, 2024, 9:00 AM EDT - 1 year ago

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 8:00 PM EDT - 1 year ago

BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

Mar 27, 2024, 4:00 PM EDT - 1 year ago

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

Mar 20, 2024, 7:00 AM EDT - 1 year ago

BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

Mar 13, 2024, 7:00 AM EDT - 1 year ago

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

Mar 12, 2024, 7:00 AM EDT - 1 year ago

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

Mar 4, 2024, 8:00 AM EST - 1 year ago

BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

Feb 8, 2024, 7:00 AM EST - 1 year ago

BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference

Jan 31, 2024, 7:00 AM EST - 1 year ago

BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference

BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders

Jan 3, 2024, 7:00 AM EST - 1 year ago

BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

Dec 19, 2023, 7:00 AM EST - 1 year ago

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes

Dec 18, 2023, 7:16 AM EST - 1 year ago

BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval

Nov 29, 2023, 7:00 AM EST - 2 years ago

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

Nov 16, 2023, 12:56 PM EST - 2 years ago

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

RIPJAWx
RIPJAWx Oct. 3 at 4:01 PM
$BCDA get ready pump coming before close and after hours 🚀🚀🚀
1 · Reply
LORAXX
LORAXX Oct. 3 at 2:17 PM
$BCDA This one is flying under the radar.
0 · Reply
Tom678
Tom678 Oct. 3 at 10:23 AM
$BCDA
0 · Reply
Raycloser
Raycloser Oct. 2 at 1:49 PM
$BCDA what’s BCDA really worth in terms of market cap
0 · Reply
NoQinyoface
NoQinyoface Oct. 2 at 1:34 PM
$BCDA This could soar within the month.
0 · Reply
DARKP00L
DARKP00L Oct. 2 at 12:04 PM
$BCDA 08:04 on Oct. 02 2025 BioCardia Regains Compliance With Nasdaq Listing Requirements #tradeideas
0 · Reply
Tom678
Tom678 Oct. 2 at 12:02 PM
$BCDA $DJT $PAVS $SCPH $TAOP BCDA amazing news !!!! 😁😁
0 · Reply
stocktuit
stocktuit Oct. 2 at 12:01 PM
$BCDA Announced Compliance with Nasdaq Listing Requirements
0 · Reply
IJ90
IJ90 Oct. 2 at 10:26 AM
$BCDA Today is the 3rd day after the Nasdaq compliance deadline — usually the most common day for official confirmation filings (8-K). BCDA stated earlier that all requirements are met, so we’re likely waiting for Nasdaq’s formal letter any moment now. Stay tuned — big update could drop today. 🚀👀
0 · Reply
Tom678
Tom678 Oct. 1 at 6:57 PM
$BCDA
0 · Reply
EZ_Money11
EZ_Money11 Oct. 1 at 1:25 PM
$BCDA $2.15-$2.25 🎯
0 · Reply
Raycloser
Raycloser Oct. 1 at 12:19 AM
$BCDA what do you folks think about the number of shares the insiders purchased in the offering?
0 · Reply
Ashsol7
Ashsol7 Sep. 30 at 7:54 PM
$BCDA insiders just bought ! thats all we have to know insiders are buying big time something is happenning 🤲🏼💵
2 · Reply
att1124
att1124 Sep. 30 at 7:49 PM
$BCDA has no cash. How is it gonna stay afloat
1 · Reply
SWCtrader
SWCtrader Sep. 30 at 7:49 PM
$BCDA ceo bought at 1.25 after offering. Sooooo theres that
0 · Reply
IJ90
IJ90 Sep. 30 at 5:25 PM
$BCDA Testing support. Waiting for the news AH or tomorrow pre-market.
0 · Reply
TheUnmaker
TheUnmaker Sep. 30 at 3:26 PM
$BCDA I said it last week.. This will go back to 1.20's
0 · Reply
SamuraiX7
SamuraiX7 Sep. 30 at 9:13 AM
$BCDA buying more
1 · Reply
Ibrahimxx
Ibrahimxx Sep. 29 at 11:44 PM
@NineLinesCat $BCDA how much do you expect it to reach this weak ?
1 · Reply
NineLinesCat
NineLinesCat Sep. 29 at 11:00 PM
$BCDA ...got another chunk...
1 · Reply
100K2022
100K2022 Sep. 29 at 5:06 PM
$BCDA added another 5500 Shares @1.41
0 · Reply
IJ90
IJ90 Sep. 29 at 12:31 PM
$BCDA 🚨 BCDA Alert 🚨 Today is the Nasdaq compliance deadline. The company confirmed all requirements are already met ✅ We’re just waiting for the official Nasdaq letter confirming continued listing. Once it drops — expect a pump! 🚀📈 Stay tuned — this could move fast! ⚡
1 · Reply